Exact Mass: 452.2522386
Exact Mass Matches: 452.2522386
Found 211 metabolites which its exact mass value is equals to given mass value 452.2522386,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Diphenoxylate
C30H32N2O2 (452.24636519999996)
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II. A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07D - Antipropulsives > A07DA - Antipropulsives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents > D000930 - Antidiarrheals
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is found in fruits. (14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is a constituent of Physalis peruviana (Cape gooseberry) Constituent of Physalis peruviana (Cape gooseberry). (14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide is found in fruits.
PA(10:0/8:0)
C21H41O8P (452.25389160000003)
PA(10:0/8:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/8:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of caprylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/10:0)
C21H41O8P (452.25389160000003)
PA(8:0/10:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/10:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of capric acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
2-Picenecarboxylic acid
(20R,22R)-21,24-epoxy-5beta-hydroxy-1-oxowitha-2,9(11),25(27)-trienolide|withametelinol-A
10-hidroxy 4,17-dihydro 17 beta-tchibangensine
C29H32N4O (452.25759819999996)
antidesmanin E|antidesmanin F|erythro-4-(2-(2-methoxy-4-((E)-3,3-dimethylpenta-1,4-dienyl)phenoxy)-1-hydroxy-3,3-dimethylpent-4-enyl)-2-methoxyphenol|threo-4-(2-(2-methoxy-4-((E)-3,3-dimethylpenta-1,4-dienyl)phenoxy)-1-hydroxy-3,3-dimethylpent-4-enyl)-2-methoxyphenol
(20R,22R)-17beta-hydroxy-1,12-dioxowitha-2,5,24-trien-26,22-olide|jaborosalactone 44
24,25,26,27-tetra-norapotirucalla-(apoeupha)-6alpha-acetoxy-7alpha-hydroxy-1,14,20,22-tetraen-21,23-epoxy-3-one|6alpha-O-acetyl-7-deacetylnimocinol
(22R)-4beta,27-dihydroxy-1-oxo-witha-2,5,16,24-tetraenolide|(4S,20S,22R)-4,27-dihydroxy-1-oxo-witha-2,5,16,24-tetraenolide
(20R,22R)-14,20-Dihydroxy-1-oxowitha-2,5,16,22-tetraenolide
3,22beta-dihydroxy-24,29-dinor-1(10),3,5-friedelatriene-2,7,21-trione
(22R,Z)-16beta,27-dihydroxy-1-oxo-witha-2,5,17(20),24-tetraenolide
3,7,9-trihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(20R,22R)-14,20-Dihydroxy-1-oxowitha-2,4,6,24-tetraenolide|14alpha,20alphaF-dihydroxy-1-oxo-22R-witha-2,4,6,24-tetraenolide
16-en-27-deoxywithaferin A|27-deoxy-Delta(16)-withaferin A|5beta,6beta-epoxy-4beta-hydroxy-1-oxo-witha-2,16,24-trienolide
1-(18-hydroxyoleoyl)-sn-glycrol 3-phosphate
C21H41O8P (452.25389160000003)
Diphenoxylate
C30H32N2O2 (452.24636519999996)
A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07D - Antipropulsives > A07DA - Antipropulsives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D005765 - Gastrointestinal Agents > D000930 - Antidiarrheals
C28H36O5_2-Picenecarboxylic acid, 1,2,3,4,4a,5,6,6a,8,12b,13,14,14a,14b-tetradecahydro-10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-, (2R,4aS,6aS,12bR,14aS,14bR)
(2R,4aS,6aR,6aS,14aS,14bR)-10,11-dihydroxy-2,4a,6a,6a,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
octadecanoic acid-1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl ester
(14alpha,17beta,20S,22R)-14,20-Epoxy-17-hydroxy-1-oxowitha-3,5,24-trienolide
GDC-0349
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2201 - mTOR Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes. GDC-0349 is a potent and selective ATP-competitive mTOR inhibitor with a Ki of 3.8 nM. GDC-0349 inhibits of both mTORC1 and mTORC2 complexes.
Bofutrelvir
COVID info from PDB, Protein Data Bank, clinicaltrial, clinicaltrials, clinical trial, clinical trials C254 - Anti-Infective Agent > C281 - Antiviral Agent C471 - Enzyme Inhibitor > C783 - Protease Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Paraminabeolide F
A withanolide that is 18,22:23,26-diepoxyergosta-1,4-diene substituted by oxo groups at positions 3, 18 and 26. It has been isolated from a Formosan soft coral Paraminabea acronocephala.
[(2R)-2-hydroxy-3-phosphonooxypropyl] (Z)-18-hydroxyoctadec-9-enoate
C21H41O8P (452.25389160000003)
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(2-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(3-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
1-[(1-ethyl-3,4-dihydro-2H-quinolin-6-yl)methyl]-3-(4-methylphenyl)-1-[2-(4-morpholinyl)ethyl]thiourea
[(E)-2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1S,6R)-1,2,6-trimethylcyclohex-2-en-1-yl]oct-5-enyl] hydrogen sulfate
C25H40O5S (452.25963100000007)
(2S,3S,3aR,9bR)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
(2R,3R,3aS,9bS)-7-[3-[dimethylamino(oxo)methyl]phenyl]-1-ethyl-3-(hydroxymethyl)-N,N-dimethyl-6-oxo-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[(E)-prop-1-enyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methyl-2-pyridin-2-ylacetamide
(1-Acetyloxy-3-phosphonooxypropan-2-yl) hexadecanoate
C21H41O8P (452.25389160000003)
(2-Nonanoyloxy-3-phosphonooxypropyl) nonanoate
C21H41O8P (452.25389160000003)
(1-Phosphonooxy-3-propanoyloxypropan-2-yl) pentadecanoate
C21H41O8P (452.25389160000003)
(1-Hexanoyloxy-3-phosphonooxypropan-2-yl) dodecanoate
C21H41O8P (452.25389160000003)
(1-Butanoyloxy-3-phosphonooxypropan-2-yl) tetradecanoate
C21H41O8P (452.25389160000003)
(1-Heptanoyloxy-3-phosphonooxypropan-2-yl) undecanoate
C21H41O8P (452.25389160000003)
(1-Pentanoyloxy-3-phosphonooxypropan-2-yl) tridecanoate
C21H41O8P (452.25389160000003)
(1-Octanoyloxy-3-phosphonooxypropan-2-yl) decanoate
C21H41O8P (452.25389160000003)
[(2R)-2-octanoyloxy-3-phosphonooxypropyl] decanoate
C21H41O8P (452.25389160000003)
phosphatidic acid 18:0
C21H41O8P (452.25389160000003)
A phosphatidic acid in which the two acyl groups contain a total of 18 carbons and no double bonds.
GSK3326595
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma[1][2][3][4][5].
(1r,2r,8s,10r,11r,15r,16s)-15-(furan-3-yl)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadeca-3,12-dien-10-yl acetate
(1r,5r,8r)-8-[(1r,3as,3bs,5as,9ar,11as)-5a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,6h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1s,2r,4r,6r,7s,10r,11r,16r,18r)-6-(furan-3-yl)-1,7,11,15,15-pentamethyl-14-oxo-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-12-en-18-yl acetate
6-(1-{3a-hydroxy-9a,11a-dimethyl-9-oxo-3h,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
(2-{2-[(1s,2r,4as,8ar)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl)oxysulfonic acid
C25H40O5S (452.25963100000007)
1-(furan-2-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
(2r,4as,6as,12br,14as,14br)-10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
(1r,3as,3br,9ar,9bs,11as)-1-[(1r)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-1-hydroxy-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,9bh,10h-cyclopenta[a]phenanthrene-9,11-dione
6-(1-{6-hydroxy-9a,11a-dimethyl-9-oxo-3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
20-methyl-7,17,21,31-tetraazaoctacyclo[19.10.1.0³,¹⁹.0⁵,¹⁷.0⁶,¹⁴.0⁸,¹³.0²²,²⁷.0²⁸,³²]dotriaconta-6(14),8,10,12,18,22,24,26-octaen-11-ol
C29H32N4O (452.25759819999996)
(1s,2r,7s,9r,11s,12s,15r,16s)-2,16-dimethyl-15-[(1s,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one
4-[(1r,2r)-2-[4-(3,3-dimethylpenta-1,4-dien-1-yl)-2-methoxyphenoxy]-1-hydroxy-3,3-dimethylpent-4-en-1-yl]-2-methoxyphenol
3,10,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,10,12,12a,13,14-hexahydro-7h-picene-2,9-dione
(1s,3br,4r,5ar,9ar,9br,11s,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl acetate
17β-hydroxy-14α,20α-epoxy-1-oxo-(22r)-witha-3,5,24-trienolide
{"Ingredient_id": "HBIN001994","Ingredient_name": "17\u03b2-hydroxy-14\u03b1,20\u03b1-epoxy-1-oxo-(22r)-witha-3,5,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC1=C(C(=O)OC(C1)C2(C3(CCC4(C3(CCC5C4CC=C6C5(C(=O)CC=C6)C)C)O2)O)C)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "10091","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5β,6β-epoxy-4β-hydroxy-1-oxowitha-2,14,24-trienolide
{"Ingredient_id": "HBIN011454","Ingredient_name": "5\u03b2,6\u03b2-epoxy-4\u03b2-hydroxy-1-oxowitha-2,14,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC12CC=C3C(C1CCC2C4COC5(CC4OC(=O)C5=C)C)CCC6(C3(C(=O)C=CC6)C)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7127","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
5β,6β-epoxy-4β-hydroxy-1-oxo-witha-2,16,24-trienolide
{"Ingredient_id": "HBIN011455","Ingredient_name": "5\u03b2,6\u03b2-epoxy-4\u03b2-hydroxy-1-oxo-witha-2,16,24-trienolide","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7128","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
6α-o-acetyl-7-deacetylnimocinol
{"Ingredient_id": "HBIN012215","Ingredient_name": "6\u03b1-o-acetyl-7-deacetylnimocinol","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "364","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
benzoylramanone
{"Ingredient_id": "HBIN017830","Ingredient_name": "benzoylramanone","Alias": "NA","Ingredient_formula": "C28H36O5","Ingredient_Smile": "CC(=O)C1CCC2(C1(C(CC3C2CC=C4C3(CCC(C4)O)C)OC(=O)C5=CC=CC=C5)C)O","Ingredient_weight": "452.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "2268","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101974123","DrugBank_id": "NA"}
(1r,3ar,3br,4r,5ar,9ar,9br,11as)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-3,7-dioxo-1h,2h,3ah,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(2-{2-[(1s,2s,4ar)-1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl)oxysulfonic acid
C25H40O5S (452.25963100000007)
4,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,8,13,14,14b-octahydropicene-3,6-dione
(1r,5r,8r)-8-[(1r,3as,3bs,5r,9ar,9bs,11as)-5-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1r,3br,4s,5r,5ar,9ar,9br,11as)-1-(furan-2-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
(6bs,8ar,9s,11r,12as,12bs,14ar)-3,9,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
(1s,2r,7s,9r,11s,12s,15r,16s)-2,16-dimethyl-15-[(1r,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one
1-acetyl-3a,7-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl benzoate
[5-(furan-3-yl)-2-[2-(1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl)ethyl]pentyl]oxysulfonic acid
C25H40O5S (452.25963100000007)
7-[10-(5-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl)undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-3,7-dioxo-1h,2h,3ah,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(6bs,8ar,9s,11s,12as,12bs,14ar)-3,9,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
(1r,3ar,3br,4r,5as,9ar,9br,11as)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-3,7-dioxo-1h,2h,3ah,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
8-{11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
[(2s)-2-{2-[(1r,2r,4as)-1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl]oxysulfonic acid
C25H40O5S (452.25963100000007)
(1r,5s,8r)-8-[(1r,3as,3bs,9ar,9bs,11r,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(9r)-2,16-dimethyl-15-[(1r,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxatetracyclo[9.7.0.0³,⁹.0¹²,¹⁶]octadeca-2,4-dien-7-one
(1r)-1-{[(2s,3e,12bs)-3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl]methyl}-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-6-ol
C29H32N4O (452.25759819999996)
(1r,2r,10r,11s,14r,15s,16s)-16-[(2r)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,7-dien-9-one
(1r,5r,8r)-8-[(11r)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
[1-(2,5,5,8a-tetramethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl)-6-(furan-3-yl)-3-methylhexan-2-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
(1r,4s,5r,5ar,9ar,9br,11as)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
15-(furan-3-yl)-2,7,7,11,16-pentamethyl-5-oxo-6-oxatetracyclo[9.7.0.0²,⁸.0¹²,¹⁶]octadeca-3,12-dien-10-yl acetate
[(1r,2s,4as,10br,12as)-8-hydroxy-2,4a,7,10b,12a-pentamethyl-9-oxo-1-(2-oxopropyl)-3,4,11,12-tetrahydro-1h-chrysen-2-yl]acetic acid
7,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,6,13,14,14b-octahydropicene-3,8-dione
(2r,4s,4ar,6as,12bs,14as,14bs)-4,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,8,13,14,14b-octahydropicene-3,6-dione
(6r)-6-{1-[(1z,2s,3as,3bs,9ar,9bs,11as)-2-hydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-ylidene]ethyl}-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
10,11-dihydroxy-2,4a,6a,12b,14a-pentamethyl-8-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid
[(5e)-2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]oct-5-en-1-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
2,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-4,5,6,13,14,14b-hexahydro-1h-picene-3,8-dione
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11s,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1s,7s)-7-[(1e,3e,5e,7e,9e)-10-[(2r,3r,6r)-3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl]undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
[(2s,3r)-1-[(4as,8as)-2,5,5,8a-tetramethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]-6-(furan-3-yl)-3-methylhexan-2-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
1-({3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl}methyl)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-6-ol
C29H32N4O (452.25759819999996)
4-[(1r,2r)-2-{4-[(1e)-3,3-dimethylpenta-1,4-dien-1-yl]-2-methoxyphenoxy}-1-hydroxy-3,3-dimethylpent-4-en-1-yl]-2-methoxyphenol
(6r)-6-[(1s)-1-[(3as,3bs,6s,9ar,9bs,11as)-6-hydroxy-9a,11a-dimethyl-9-oxo-3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
[(5e)-2-[3-(furan-3-yl)propyl]-6-methyl-8-(2,6,6-trimethylcyclohex-2-en-1-yl)oct-5-en-1-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
6-(1-{3a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3bh,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-1-hydroxyethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
(1s,3bs,4r,5s,5as,9as,9bs,11ar)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
6-(furan-3-yl)-1,7,11,15,15-pentamethyl-14-oxo-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-12-en-18-yl acetate
(1s,2r,6s,7r,9r,11s,12s,16s)-15-[(1s)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-6-hydroxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadeca-4,14-dien-3-one
(1r,2s,5s,6r,10r,11s,12r,15r,19s)-6-(furan-3-yl)-11-(methoxymethoxy)-1,5,10,15-tetramethyl-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadeca-8,16-dien-18-one
(1r,2r,10r,11s,14r,15s,16r)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-15-hydroxy-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,6-dien-9-one
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11r,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
{2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1s,6r)-1,2,6-trimethylcyclohex-2-en-1-yl]oct-5-en-1-yl}oxysulfonic acid
C25H40O5S (452.25963100000007)
1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
2,16-dimethyl-15-{1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl}-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one
methyl (6bs,8as,11r,12ar,12bs,14ar)-6b,8a,11,12b,14a-pentamethyl-2,4-dioxo-7h,8h,9h,10h,12h,12ah,13h,14h-phenanthro[2,1-f]isochromene-11-carboxylate
(1r,2r,10r,11s,14r,15s,16s)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-15-hydroxy-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,7-dien-9-one
(6s)-6-[(1r)-1-[(1s,6s,9ar,9bs,11as)-1,6-dihydroxy-9a,11a-dimethyl-9-oxo-2h,3h,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-3,4-dimethyl-5,6-dihydropyran-2-one
(1s,9r,11s,12s,15r,16s)-2,16-dimethyl-15-[(1r,4r,5r)-1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl]-8-oxatetracyclo[9.7.0.0³,⁹.0¹²,¹⁶]octadeca-2,4-dien-7-one
(2r,4as,6as,12br,14as,14br)-2,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-4,5,6,13,14,14b-hexahydro-1h-picene-3,8-dione
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11s,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(6bs,7s,8ar,9s,11r,12as,12bs,14as)-3,7,9-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(6bs,8ar,10s,11s,12as,12bs,14ar)-3,10,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,10,12,12a,13,14-hexahydro-7h-picene-2,9-dione
(1r,4s,6r,7r)-7-[(1e,3e,5e,7e,9e)-10-[(2r,3s,6s)-3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl]undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
6-(1-{1,6-dihydroxy-9a,11a-dimethyl-9-oxo-2h,3h,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-3,4-dimethyl-5,6-dihydropyran-2-one
3,7,9-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(1s,7s)-7-[(1e,3e,5e,7e,9e)-10-[(2s,5r,6r)-5-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl]undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
(1r,4r,5r,7s)-7-[(1r,3as,3bs,9ar,9bs,11as)-1-hydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3ah,3bh,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-4-hydroxy-4,5-dimethyl-2-oxabicyclo[3.2.1]octan-3-one
[8-hydroxy-2,4a,7,10b,12a-pentamethyl-9-oxo-1-(2-oxopropyl)-3,4,11,12-tetrahydro-1h-chrysen-2-yl]acetic acid
[(2s,5e)-2-[3-(furan-3-yl)propyl]-6-methyl-8-[(1s)-2,6,6-trimethylcyclohex-2-en-1-yl]oct-5-en-1-yl]oxysulfonic acid
C25H40O5S (452.25963100000007)
(6r)-6-[(1r)-1-[(1s,3ar,3br,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3bh,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3,4-dimethyl-5,6-dihydropyran-2-one
6-(1-{2-hydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-ylidene}ethyl)-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
7-[10-(3-hydroxy-3,5,6-trimethyl-2,6-dihydropyran-2-yl)undeca-1,3,5,7,9-pentaen-1-yl]-4,6,7-trimethyl-2-oxabicyclo[2.2.1]heptane-3,5-dione
(1s,2r,6s,7r,9r,11r,15r,16r)-15-[(1s)-1-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-6-hydroxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadeca-4,12-dien-3-one
(1s,2r,4r,6s,7s,10r,11r,16r,18r)-6-(furan-3-yl)-1,7,11,15,15-pentamethyl-14-oxo-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadec-12-en-18-yl acetate
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11r,11as)-11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(6r)-6-[(1r)-1-[(3ar,3br,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-9-oxo-3h,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3,4-dimethyl-5,6-dihydropyran-2-one
(1r,2r,10r,11s,14r,15r,16r)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-15-hydroxy-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,7-dien-9-one
(1s)-1-{[(2s,3e,12bs)-3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl]methyl}-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-6-ol
C29H32N4O (452.25759819999996)
(2-{2-[(1r,2r,4as)-1,2,5,5-tetramethyl-2,3,4,4a,6,7-hexahydronaphthalen-1-yl]ethyl}-5-(furan-3-yl)pentyl)oxysulfonic acid
C25H40O5S (452.25963100000007)
{2-[3-(furan-3-yl)propyl]-6-methyl-8-(2,6,6-trimethylcyclohex-2-en-1-yl)oct-5-en-1-yl}oxysulfonic acid
C25H40O5S (452.25963100000007)
(2s,3r,4s,11's,14's,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2',5',12'-triene-4',7'-dione
(1r,3br,4s,5r,5as,9ar,9br,11as)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
8-{5-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1's,2s,3r,4s,10'r,11'r,14's,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2',5',12'-triene-4',7'-dione
(6r)-6-[(1r)-1-[(1s,3br,9ar,9bs,11ar)-9a,11a-dimethyl-9-oxo-1h,2h,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one
2,16-dimethyl-15-{1-methyl-8-methylidene-7-oxo-2,6-dioxabicyclo[3.3.1]nonan-4-yl}-8-oxatetracyclo[9.7.0.0³,⁹.0¹²,¹⁶]octadeca-2,4-dien-7-one
(1r,3br,4s,5r,5ar,9ar,9br,11as)-1-(furan-3-yl)-5-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2',5',12'-triene-4',7'-dione
3,9,11-trihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
(1s,3as,3bs,7s,9ar,9bs,11r,11as)-1-acetyl-3a,7-dihydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl benzoate
(2r,4as,6as,12bs,14as,14br)-7,10,11-trihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,6,13,14,14b-octahydropicene-3,8-dione
15-[1-(4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl)ethyl]-6-hydroxy-2,16-dimethyl-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadeca-4,14-dien-3-one
8-{11-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
8-{5a-hydroxy-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,5h,6h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1r,2r,10r,11s,14r,15s,16s)-16-[(2r)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,6-dien-9-one
(1r,3br,4s,5r,5as,9ar,9br,11as)-1-(furan-3-yl)-4-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-5-yl acetate
4-hydroxy-7-{1-hydroxy-9a,11a-dimethyl-9-oxo-2h,3h,3ah,3bh,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-4,5-dimethyl-2-oxabicyclo[3.2.1]octan-3-one
[(2s)-5-(furan-3-yl)-2-[2-(1,2,5,5-tetramethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl)ethyl]pentyl]oxysulfonic acid
C25H40O5S (452.25963100000007)